Selinexor Prior to CAR-T Cell Therapy in Myeloma | Bruno Costa, MD | IMS 2024

Good morning, good morning, good morning. My name is Bruno Costa. I'm a palliative care fellow at the Mount Sinai Hospital and I'm a myeloma research affiliate at Marisolon-Katherine and Mount Sinai's Stitch Cancer Institute. One ongoing challenge when caring for patients with rare lives refractory multiple myeloma is how to best sequence different treatments so we can get the best outcomes in the long run. Another ongoing challenge is how to best strike a balance between decreasing the burden of disease and maintaining the efficacy and the function of T cells prior to CAR T cell therapy. In our collaboration between Mount Sinai's Stitch Cancer Institute and Cleveland Clinic Foundation we investigated whether administering a salinexrin containing regimen before CAR T cell therapy could impact the outcomes of the CAR T line of therapy. In our study we observed that for patients that receive salinexrin prior to CAR T cell therapy there is no negative impact in the outcomes from CAR T cell therapy either safety outcomes like CRS rates and ICANN rates or efficacy outcomes like progression free survival overall survival or response rates. Our study is still exploratory so prospective studies including clinical trials are still needed to investigate whether administering salinexrin before CAR T cell therapy could improve CAR T outcomes and those studies should also include endpoints that are laboratory endpoints or pre-clinical endpoints so we can best know and investigate how the drug can impact the function of T cells.